Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?

Pellicelli AM, Romano M, Guarascio P, Vignally P.

J Hepatol. 2012 Sep;57(3):704-5. doi: 10.1016/j.jhep.2012.03.008. No abstract available.

2.

The "pegylated" story continues--perhaps because both ends (α2a and α2b) are true?

Reiberger T, Peck-Radosavljevic M.

J Hepatol. 2012 Jul;57(1):226-8; author reply 229. doi: 10.1016/j.jhep.2012.01.026. No abstract available.

3.
4.

Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.

Rivero-Juarez A, Lopez-Cortes LF, Girón-Gonzalez JA, Pineda JA, Rivero A; Grupo Andaluz para Estudio de Hepatitis Víricas (HEPAVIR) de Sociedad Andaluza de Enfermedades Infecciosas..

Lancet Infect Dis. 2014 Jan;14(1):13-4. doi: 10.1016/S1473-3099(13)70359-1. No abstract available.

PMID:
24355031
5.

[Treatment for chronic hepatitis C, more opportunity, more challenge].

Wei L.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):481-3. Chinese. No abstract available.

PMID:
19912676
6.

Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.

Fouad YM, Khalaf H, Ibraheem H, Rady H, Helmy AK.

Int J Infect Dis. 2012 Jan;16(1):e67-71. doi: 10.1016/j.ijid.2011.09.022.

7.

Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.

Hrachovec J, Patel P.

Gastroenterology. 2003 Jun;124(7):2003-4; author reply 2004-5. No abstract available.

PMID:
12812198
8.

Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: further evidence in decompensation cirrhosis.

Ji F, Zhang S, Deng H, Li Z.

J Hepatol. 2013 Jun;58(6):1262-4. doi: 10.1016/j.jhep.2013.01.041. No abstract available.

9.

Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL.

Lo Nigro L, La Spina M, Mirabile E, Pisana P, Schilirò G, Guardo P.

Pediatr Blood Cancer. 2004 Aug;43(2):185. No abstract available.

PMID:
15236293
10.

Education by a nurse increases the adherence to therapy in chronic hepatitis C patients.

Alavian SM, Aalaei-Andabili SH.

Clin Gastroenterol Hepatol. 2012 Feb;10(2):203; author reply 203. doi: 10.1016/j.cgh.2011.08.004. No abstract available.

PMID:
21839708
11.

A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C.

Dai CY, Chuang WL, Yu ML.

Hepatology. 2014 Dec;60(6):2128-9. doi: 10.1002/hep.27096. No abstract available.

PMID:
24585417
12.

HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment.

Zignego AL, Cozzi A, Carpenedo R, Giannini C, Rosselli M, Biagioli T, Aldinucci A, Laffi G, Moroni F.

Dig Liver Dis. 2007 Sep;39 Suppl 1:S107-11.

PMID:
17936210
13.

[HCV-HBV infection].

Imamura M, Chayama K.

Nihon Rinsho. 2006 Jul;64(7):1310-3. Review. Japanese.

PMID:
16838649
14.

Boceprevir for HCV in patients with HIV: where next?

Osinusi A, Naggie S.

Lancet Infect Dis. 2013 Jul;13(7):563-4. doi: 10.1016/S1473-3099(13)70162-2. No abstract available.

PMID:
23768748
15.

Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools.

Boglione L, De Nicolò A, Di Perri G, D'Avolio A.

J Hepatol. 2014 Jul;61(1):178-9. doi: 10.1016/j.jhep.2014.02.035. No abstract available.

16.

Reply to "triple or dual therapy for HCV-1 naive patients? Optimizing selection tools".

Palmieri O, Valvano MR, Margaglione M, Andriulli A.

J Hepatol. 2014 Jul;61(1):179-80. doi: 10.1016/j.jhep.2014.03.020. No abstract available.

17.
18.

Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.

Kim DY.

Gut Liver. 2014 Jul;8(4):335-6. doi: 10.5009/gnl.2014.8.4.335. No abstract available.

19.

[Do the interferons have an antifibrotic action? The hepatologist's point of view].

Poynard T.

Rev Med Interne. 2002 Nov;23 Suppl 4:517s-521s. Review. French.

PMID:
12481408
20.

[Treatment of cirrhotics].

Galdame O, Jorge A, Sordá J.

Acta Gastroenterol Latinoam. 2005 Jun;35 Suppl 1:S42-5. Spanish. No abstract available.

PMID:
20214300
Items per page

Supplemental Content

Support Center